References
- Rucinski B., Niewiarowski S., James P., Walz D. A. and Budzynski A. Z. (1979). Antiheparin proteins secreted by human platelets. Purification, characterization, and radioimmunoassay. Blood, 53, 47–62.
- Cella G., Meyers C. J., Prosdocimi M. and Sasahara A. A. (1987). Human platelet factor 4 and protamine sulphate interaction with glycosaminoglycans in the rabbit. Eur. J. Clin. Invest., 17, 548–54.
- Marcum J. A., McKenney J. and Rosenberg R. D., The acceleration of thrombin-antithrombin complex formation in rat hindquarter via naturally occurring heparin-like molecules bound to the endothelium. J. Clin. Invest., 73, 341–50.
- Cella G., Colby S. I., Tayor A. D., McCraken L., Parisi A. F. and Sasahara A. A. (1985). Thromb. Res., 29, 499–509.
- Rucinski B., Knight L. C. and Niewiarowski S. (1986). Clearance of human platelet factor 4 by liver and kidney: its alteration by heparin. Am. J. Physiol., 251, H800–7.
- Broze G. J. Jr. and Miletich J. P. (1987). Characterization of the inhibition of tissue factor in serum. Blood, 69, 150–5.
- Novotny W. F., Girard T. J., Miletich J. P. and Broze G. J. Jr. (1988). Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood, 72, 2020–5.
- Novotny W. F., Brown S. G., Miletich J. P., Rader D. J. and Broze G. J. Jr. (1991). Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood, 78, 387–93.
- Sandset P. M., Abildgaard U. and Larsen M. L. (1988). Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb. Res., 50, 803–13.
- Lindahl A. K., Abildgaard U. and Stokke G. (1990). Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb. Res., 59, 651–6.
- Warn-Cramer B. J., Maki S. L. and Rappaport S. I. (1993). Heparin-releasable and platelet pools of tissue factor pathway inhibitor in rabbit. Thromb. Haemosl., 69, 221–6.
- Bara L., Bloch M. F., Zitoun Z., Samama M., Corlignon F., Frydman A., Uzan A. and Bouthier J. (1993). Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb. Res., 69, 443–52.
- Celia G., Stevanato F., Paolini R., Veronese P. and Strauss W. E. (1991). Platelet factor 4 release by heparin in patients with thrombocytosis. J. Vasc. Med. Biol., 3, 134–8.
- Murphy S., Iland H., Rosenthal D. and Laszlo J. (1986). Essential thrombocythemia: an interim report from the polycythemia vera study group. Sem. Haematol., 23, 177–82.
- Sanset P. M., Larsen M. L., Abildgaard U., Lindahl A. K. and Odegard O. R. (1991). Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul. Fibrinol., 2, 425–33.
- Yin E. T. (1985). Appraisal of clot-based and amidolytic anti-Xa methods for the monitoring heparin and its derivatives. Sem. Thromb. Haemost., 11, 243–4.
- Kristensen H. I., Ostergaard P., Nordfang O., Abildgaard U. and Lindahl A. K. (1992). Effect of tissue factor pathway inhibitor (TEPI) in the HEPTEST assay and in an amiodyltic antifactor Xa assay for LMW heparin. Thromb. Haemost., 68, 310–14.
- Ludlam C. A. and Cash J. D. (1976). Studies on the liberation of β-thromboglobulin from human platelets in vitro. Brit. J. Haematol., 33, 239–47.
- Novotny W. F., Day K., Wun T. C. and Nieces G. (1990). Platelet LAC1 is present in novel granules. Blood, 76(Suppl 1), 469a.
- Denton J., Lane D. A., Thunenberg L., Slater A. M. and Lindahl U. (1983). Binding of platelet factor 4 to heparin oligosaccharides. Biochem. J., 209, 455–60.
- Zitoun D., Bara L., Bloch F. M., Choay J. and Samama M. M. (1993). Intravenous injection of pentasaccharide (PS) does not increase TFPI activity in rabbits. Thromb. Haemost., 69, 768 (abstract).